Search

Author/Creator Donskov, Frede

1. A five-factor biomarker profile obtained week 4–12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. (3rd March 2016)

Authors:
Soerensen, Anne V.; Geertsen, Poul F.; Christensen, Ib J.; Hermann, Gregers G.; Jensen, Niels V.; Fode, Kirsten; Petersen, Astrid; Sandin, Rickard; Donskov, Frede
Journal:
Acta oncologica
Issue:
Volume 55:Number 3(2016)
Page Start:
341
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. (4th May 2018)

Authors:
Donskov, Frede; Jensen, Niels Viggo; Smidt-Hansen, Torben; Brøndum, Line; Geertsen, Poul
Journal:
Acta oncologica
Issue:
Volume 57:Number 5(2018)
Page Start:
589
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Issue 10358 (1st October 2022)

Authors:
Pal, Sumanta Kumar; Uzzo, Robert; Karam, Jose Antonio; Master, Viraj A; Donskov, Frede; Suarez, Cristina; Albiges, Laurence; Rini, Brian; Tomita, Yoshihiko; Kann, Ariel Galapo; Procopio, Giuseppe; Massari, Francesco; Zibelman, Matthew; Antonyan, Igor; Huseni, Mahrukh; Basu, Debasmita; Ci, Bo; Leu...
Journal:
Lancet
Issue:
Volume 400:Issue 10358(2022)
Page Start:
1103
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Issue 10189 (15th June 2019)

Authors:
Rini, Brian I; Powles, Thomas; Atkins, Michael B; Escudier, Bernard; McDermott, David F; Suarez, Cristina; Bracarda, Sergio; Stadler, Walter M; Donskov, Frede; Lee, Jae Lyun; Hawkins, Robert; Ravaud, Alain; Alekseev, Boris; Staehler, Michael; Uemura, Motohide; De Giorgi, Ugo; Mellado, Begoña; Por...
Journal:
Lancet
Issue:
Volume 393:Issue 10189(2019)
Page Start:
2404
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. (18th January 2021)

Authors:
Gan, Chun Loo; Dudani, Shaan; Wells, J. Connor; Donskov, Frede; Pal, Sumanta K.; Dizman, Nazli; Rathi, Nityam; Beuselinck, Benoit; Yan, Flora; Lalani, Aly‐Khan A.; Hansen, Aaron; Szabados, Bernadett; de Velasco, Guillermo; Tran, Ben; Lee, Jae Lyun; Vaishampayan, Ulka N.; Bjarnason, Georg A.; Suba...
Journal:
Cancer medicine
Issue:
Volume 10:Number 4(2021)
Page Start:
1212
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Issue 7 (July 2016)

Authors:
Choueiri, Toni K; Escudier, Bernard; Powles, Thomas; Tannir, Nizar M; Mainwaring, Paul N; Rini, Brian I; Hammers, Hans J; Donskov, Frede; Roth, Bruce J; Peltola, Katriina; Lee, Jae Lyun; Heng, Daniel Y C; Schmidinger, Manuela; Agarwal, Neeraj; Sternberg, Cora N; McDermott, David F; Aftab, Dana T;...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 7(2016:Jul.)
Page Start:
917
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy. (August 2013)

Authors:
Rasmussen, Susanne; Donskov, Frede; Pedersen, Johannes W.; Wandall, Hans H.; Buus, Søren; Harndahl, Mikkel; Braendstrup, Peter; Claesson, Mogens H.; Pedersen, Anders Elm
Journal:
Immunopharmacology and immunotoxicology
Issue:
Volume 35:Number 4(2013:Aug.)
Page Start:
487
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Characterizing the outcomes of metastatic papillary renal cell carcinoma. (16th April 2017)

Authors:
Connor Wells, John; Donskov, Frede; Fraccon, Anna P.; Pasini, Felice; Bjarnason, Georg A.; Beuselinck, Benoit; Knox, Jennifer J.; Rha, Sun Young; Agarwal, Neeraj; Bowman, Isaac Alex; Lee, Jae‐Lyun; Pal, Sumanta K.; Srinivas, Sandy; Scott Ernst, Douglas; Vaishampayan, Ulka N.; Wood, Lori A.; Simps...
Journal:
Cancer medicine
Issue:
Volume 6:Number 5(2017:May)
Page Start:
902
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Issue 11 (5th April 2022)

Authors:
Motzer, Robert J.; McDermott, David F.; Escudier, Bernard; Burotto, Mauricio; Choueiri, Toni K.; Hammers, Hans J.; Barthélémy, Philippe; Plimack, Elizabeth R.; Porta, Camillo; George, Saby; Powles, Thomas; Donskov, Frede; Gurney, Howard; Kollmannsberger, Christian K.; Grimm, Marc‐Oliver; Barrios,...
Journal:
Cancer
Issue:
Volume 128:Issue 11(2022)
Page Start:
2085
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗